An Ontario Clinical Oncology Group (OCOG) randomized controlled trial (RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinoma metastases (CAM).

3520 Background: Advances in chemotherapy and surgery have increased the number of colorectal cancer patients eligible for hepatic resection. Detection of extrahepatic metastases is important to avoid futile liver surgery. Uncontrolled studies have reported change of management in 20-30% of cases when PET staging is compared with CT alone. There are no large RCTs assessing the additional benefits of PET/CT after the decision to operate based on high quality CT imaging. Methods: A multicenter trial where 404 patients with CAM deemed eligible for hepatic surgery were randomized 2:1 to PET (with a PET/CT) or no PET. Abnormal PET findings were characterized with further imaging +/- biopsy. Surgeons reported planned and actual surgery at specific times in both arms. The primary objective was to determine the proportion of patients who had a change in management resulting from PET defined as cancelled liver surgery (including open/close surgery as a result of PET) and more extensive liver or additional organs s...